

Clinical trials of anti inflammatory drugs for post myocardial infarction in all type of patients

TrialResults-center www.trialresultscenter.org

1 Interleukin-1 inhibition

| Trial | Treatments | Patients | Trials design and methods |
|--|---|---|---------------------------|
| canakinumab vs placebo | | | |
| CANTOS , 2017 [NCT01327846] n=10066 follow-up: 36 months | Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months versus placebo | Stable Post-myocardial Infarction Patients With Elevated hsCRP | double-blind |

References

CANTOS, 2017:

Ridker PM, Thuren T, Zalewski A, Libby P Interleukin-1? inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605 [[21982649](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.